Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
5,434,244
-
Total 13F shares
-
2,418,438
-
Share change
-
-1,192,056
-
Total reported value
-
$4,501,000
-
Put/Call ratio
-
2.1%
-
Price per share
-
$1.86
-
Number of holders
-
38
-
Value change
-
-$2,768,399
-
Number of buys
-
15
-
Number of sells
-
22
Institutional Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q1 2022
As of 31 Mar 2022,
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) was held by
38 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,418,438 shares.
The largest 10 holders included
VANGUARD GROUP INC, KENNEDY CAPITAL MANAGEMENT, INC., RENAISSANCE TECHNOLOGIES LLC, MORGAN STANLEY, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, and GROUP ONE TRADING, L.P..
This page lists
38
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.